- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03654612
Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies (Y-HR2017-025)
A Single Arm,Open Clinical Study of Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies
Studieöversikt
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Liu Ping, doctor
- Telefonnummer: 13975157508
- E-post: CYRIL0820@sina.com
Studera Kontakt Backup
- Namn: Liu Bin, doctor
- Telefonnummer: 13973127325
- E-post: Binglang3351@qq.com
Studieorter
-
-
Hunan
-
Changsha, Hunan, Kina, 410011
- Rekrytering
- The second xiangya hospital
-
Kontakt:
- ping liu
- Telefonnummer: (+86)13975157508
- E-post: cyril0820@sina.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥ 18 years old, male or female;
- Pathologically diagnosed advanced head and neck malignant tumors with measurable lesions (spiral CT scan ≥10mm, meeting RECIST 1.1 criteria);
- Late, recurrent or metastatic malignant tumors of the head and neck that are inoperable and radiotherapy;
- According to CTCAE 4.0 and the patient's complaint, the investigator judged patients who were intolerable by second-line combined chemotherapy;
- ECOG PS: 0-1 points;
Baseline blood and biochemical indicators meet the following criteria:
Hemoglobin ≥ 80g/L, Absolute neutrophil count (ANC) ≥1.5×109/L, Platelets ≥ 90×109/L, ALT, AST ≤ 2.5 times the normal upper limit, ≤ 5 times the normal upper limit (with liver metastases), Serum total bilirubin ≤ 1.5 times the normal upper limit, Serum creatinine ≤ 1.5 times the normal upper limit, Serum albumin ≥ 30g / L;
- The expected survival period is ≥3 months;
- Women of childbearing age must undergo a pregnancy test (serum or urine) within 7 days prior to enrollment and the results are negative, and are willing to use appropriate methods of contraception during the trial and 8 weeks after the last administration of the test drug. For men, surgery should be sterilized, or consent should be used during the trial and 8 weeks after the last administration of the test drug.
- Subjects volunteered to participate in the study, signed informed consent, and were well-adhered to follow-up.
Exclusion Criteria:
- A person who has been confirmed to be allergic to apatinib and/or its excipients;
- Patients with hypertension and antihypertensive medication can not be reduced to normal range (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg), with grade I or higher coronary heart disease, grade I arrhythmia (including QTc interval prolongation) Male > 450 ms, female > 470 ms) and grade I cardiac insufficiency; urine protein positive patients;
- Have multiple factors affecting oral medications (such as inability to swallow, nausea, vomiting, chronic diarrhea, and intestinal obstruction);
- Patients who have used apatinib or tigeo in the first line
- abnormal blood coagulation (INR>1.5, APTT>1.5 ULN), with bleeding tendency;
- Patients with central nervous system metastases;
- Pregnant or lactating women;
- Patients with other malignancies within 5 years;
- Patients with a history of psychotropic substance abuse who are unable to quit or have a mental disorder;
- Patients who have participated in other drug clinical trials within 4 weeks;
- Have received VEGFR inhibitors such as sorafenib and sunitinib;
- According to the investigator's judgment, there are serious patients who are at risk to the patient's safety or affect the patient's accompanying disease to complete the study;
- The investigator believes that it is not suitable for inclusion.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Apatinib+S-1
Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.
|
Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
PFS
Tidsram: 40 months
|
Progression free survival
|
40 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
OS
Tidsram: 40 months
|
Overall survival
|
40 months
|
Samarbetspartners och utredare
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ChinaIMF-LP02
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Apatinib
-
Elevar TherapeuticsAvslutadAdenoid cystiskt karcinomFörenta staterna, Korea, Republiken av
-
Peking University Cancer Hospital & InstituteRekrytering
-
The First Affiliated Hospital of Zhengzhou UniversityRekryteringEsophageal Cancer av AJCC V8 StageKina
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.Rekrytering
-
The First Affiliated Hospital of Zhengzhou UniversityRekrytering
-
Peking Union Medical College HospitalAvslutad
-
Ruijin HospitalAktiv, inte rekryterandeGastric and Gastroesophageal Junction (GEJ) AdenocarcinomKina
-
Peking Union Medical College HospitalAvslutadKolangiokarcinom | Hepatobiliär neoplasma | Gallvägscancer | BiomarkörKina
-
Lei LiAvslutadKemoterapi | Återkommande livmoderhalscancer | Apatinib | Riktad terapi | Ihållande avancerad livmoderhalscancer | Vaskulär endotelial tillväxtfaktor 2-hämmareKina
-
Peking Union Medical College HospitalJiangsu HengRui Medicine Co., Ltd.RekryteringGestationell trofoblastisk neoplasiKina